

Validation of the revised international prognostic score thrombocytopenia (<scp>IPSET</scp>â€thrombosis) in

American Journal of Hematology

91, 390-394

DOI: 10.1002/ajh.24293

Citation Report

#	ARTICLE	IF	CITATIONS
1	Refining prognostication of thrombosis in <scp>ET</scp>. American Journal of Hematology, 2016, 91, 361-363.	4.1	8
2	Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thrombosis Research, 2016, 140, S71-S75.	1.7	28
3	Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia. Leukemia and Lymphoma, 2017, 58, 503-504.	1.3	1
4	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leukemia and Lymphoma, 2017, 58, 2786-2798.	1.3	17
5	Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia. Experimental and Therapeutic Medicine, 2017, 13, 947-951.	1.8	3
6	Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia, 2017, 31, 1845-1854.	7.2	25
7	Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. British Journal of Haematology, 2017, 176, 352-364.	2.5	23
8	Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. Current Hematologic Malignancy Reports, 2017, 12, 397-405.	2.3	9
9	Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic Proceedings, 2017, 92, 1283-1290.	3.0	53
10	Pregnancy and myeloproliferative neoplasms : A retrospective monocentric cohort. Obstetric Medicine, 2017, 10, 165-169.	1.1	10
11	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
12	Essential thrombocythemia treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 2.	6.2	85
13	SOHO State-of-the-Art Update and Next Questions: MPN. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 1-12.	0.4	7
14	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. Journal of Clinical Oncology, 2018, 36, 3361-3369.	1.6	54
15	Emerging therapies for the treatment of essential thrombocythemia. Expert Opinion on Orphan Drugs, 2018, 6, 567-575.	0.8	0
16	JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology American Society of Hematology Education Program, 2018, 2018, 110-117.	2.5	7
17	Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. European Journal of Haematology, 2018, 101, 508-513.	2.2	10
18	Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Cancer Treatment and Research, 2019, 179, 159-178.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Comparison between thrombotic risk scores in essential thrombocythemia and survival implications. <i>Hematological Oncology</i> , 2019, 37, 434-437.	1.7	10
20	Age at diagnosis is an important prognostic factor in Philadelphia \hat{c} negative Myeloproliferative Neoplasms. <i>European Journal of Haematology</i> , 2019, 103, 140-141.	2.2	0
21	The Role of New Technologies in Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2019, 9, 321.	2.8	37
22	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019, 94, 599-610.	3.0	103
23	Developments in diagnosis and treatment of essential thrombocythemia. <i>Expert Review of Hematology</i> , 2019, 12, 159-171.	2.2	11
24	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 397-406.	2.5	17
25	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019, 3, 1729-1737.	5.2	105
26	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. <i>Blood</i> , 2019, 134, 1902-1911.	1.4	20
27	Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. <i>Hematology Reports</i> , 2019, 11, 8281.	0.8	17
28	Essential Thrombocythemia. <i>New England Journal of Medicine</i> , 2019, 381, 2135-2144.	27.0	106
29	High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. <i>Annals of Hematology</i> , 2019, 98, 93-100.	1.8	24
30	High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 80, 102368.	1.4	14
31	<p>Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12367-12382.	2.0	39
32	Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093520.	1.7	4
33	Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk \hat{c} stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 1599-1613.	4.1	204
34	Thrombocytosis and Thrombosis: Is There Really a Correlation?. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 261-267.	2.3	14
35	Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis. <i>Molecular Biology Reports</i> , 2020, 47, 4767-4778.	2.3	6
36	Prognostic models in the myeloproliferative neoplasms. <i>Blood Reviews</i> , 2020, 42, 100713.	5.7	10

#	ARTICLE	IF	CITATIONS
37	Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera. <i>International Journal of Hematology</i> , 2020, 112, 377-384.	1.6	24
38	Current management strategies for polycythemia vera and essential thrombocythemia. <i>Blood Reviews</i> , 2020, 42, 100714.	5.7	35
39	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. <i>Cancers</i> , 2020, 12, 1746.	3.7	18
40	Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera. <i>Leukemia and Lymphoma</i> , 2020, 61, 1744-1747.	1.3	7
41	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 21.	6.2	35
42	The new WHO classification for essential thrombocythemia calls for revision of available evidences. <i>Blood Cancer Journal</i> , 2020, 10, 22.	6.2	19
43	CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020008.	1.3	14
44	The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors. <i>Advances in Hematology</i> , 2020, 2020, 1-5.	1.0	5
45	Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. <i>American Journal of Hematology</i> , 2021, 96, 354-366.	4.1	22
46	Successive development of ischemic stroke and hemorrhagic stroke in a patient with essential thrombocythemia: a case report. <i>Journal of International Medical Research</i> , 2021, 49, 030006052098771.	1.0	1
47	Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas. <i>Medical Principles and Practice</i> , 2021, 30, 412-421.	2.4	3
48	Manifestações orais nas doenças mieloproliferativas: Uma revisão de literatura. <i>Research, Society and Development</i> , 2021, 10, e0710514581.	0.1	0
49	Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. <i>Hemato</i> , 2021, 2, 305-328.	0.6	3
50	Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 665037.	2.8	10
51	Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Hamostaseologie</i> , 2021, 41, 197-205.	1.9	2
52	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. <i>Cells</i> , 2021, 10, 1962.	4.1	11
53	Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in <i>JAK2</i> -Mutated Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , 2021, 27, 5708-5717.	7.0	7
54	Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis. <i>Annals of Hematology</i> , 2021, 100, 2699-2706.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. <i>American Journal of Hematology</i> , 2021, 96, 1472-1480.	4.1	20
56	Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1190-1203.	1.7	9
57	Essential thrombocythemia with portal vein thrombosis and splenic infarction successfully treated with platelet apheresis. <i>BMJ Case Reports</i> , 2021, 14, e245267.	0.5	1
58	Low-Risk Essential Thrombocythemia: A Comprehensive Review. <i>HemaSphere</i> , 2021, 5, e521.	2.7	11
59	Thrombocytosis and thrombosis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 383-388.	0.1	0
60	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the Ph1-negative Myeloproliferative Neoplasms Latium Group. <i>European Journal of Haematology</i> , 2020, 105, 335-343.	2.2	8
61	Essential Thrombocythemia. <i>Molecular Pathology Library</i> , 2018, , 141-154.	0.1	0
62	Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm. <i>Hematology & Transfusion International Journal</i> , 2018, 6, .	0.1	0
63	1. Pathophysiology and Treatment Strategies of Myeloproliferative Neoplasms. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1672-1684.	0.0	0
64	Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome. <i>Journal of Hematology and Clinical Research</i> , 2019, 3, 053-059.	0.4	0
65	What's in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1279-1284.	4.9	8
66	Precision Medicine in BCR-ABL1 Negative Myeloproliferative Neoplasms. <i>Healthbook TIMES Oncology Hematology</i> , 2020, , .	0.1	0
67	Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. <i>International Review of Cell and Molecular Biology</i> , 2021, 365, 1-69.	3.2	13
68	The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. <i>Plasmatology</i> , 2020, 13, 263485352097821.	0.4	22
70	Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH. <i>Clinical and Translational Oncology</i> , 2022, 24, 770-783.	2.4	1
71	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2022, 97, E35.	4.1	18
72	Impact of JAK2V617F Mutational on Haematologic Features in Sudanese Patients with Essential Thrombocythemia and Thrombotic Risk Assessment. <i>Journal of Bioscience and Applied Research</i> , 2020, 6, 263-273.	0.2	0
73	JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis. <i>Thrombosis Research</i> , 2022, 211, 1-5.	1.7	6

#	ARTICLE	IF	CITATIONS
74	Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions. <i>Annals of Hematology</i> , 2022, 101, 935-951.	1.8	5
77	Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Leukemia Research</i> , 2022, , 106883.	0.8	0
78	Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210979.	1.7	1
79	Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study. <i>British Journal of Haematology</i> , 2022, 199, 86-94.	2.5	5
80	Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia. <i>Hematology Reports</i> , 2022, 14, 265-269.	0.8	1
81	Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 155-169.	2.3	12
82	Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211174.	1.7	2
83	The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2023, 98, 166-179.	4.1	27
84	Leukocytosis and MPNs: Where do we stand?. <i>Leukemia and Lymphoma</i> , 2023, 64, 564-572.	1.3	1
85	Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 263-272.	2.1	4
86	Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study. <i>Journal of Thrombosis and Thrombolysis</i> , 0, , .	2.1	0
87	Prognostication in myeloproliferative neoplasms, including mutational abnormalities. <i>Blood Research</i> , 2023, 58, S37-S45.	1.3	1
88	Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology. <i>Cells</i> , 2023, 12, 946.	4.1	2
89	<scp>ABO</scp> blood group type and risk of venous thrombosis in essential thrombocythemia. <i>British Journal of Haematology</i> , 2023, 202, 699-703.	2.5	4
90	Molecular findings in myeloid neoplasms. <i>International Journal of Laboratory Hematology</i> , 2023, 45, 442-448.	1.3	1
91	Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. <i>Annals of Hematology</i> , 0, , .	1.8	0
92	<i>MPL</i> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. <i>Hematology</i> , 2023, 28, .	1.5	2
93	The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study. , 2023, 3, 54-61.		0

#	ARTICLE	IF	CITATIONS
94	Pathologies h�matologiques. , 2022, , 313-373.		0
95	Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients. Medicina (Lithuania), 2023, 59, 1300.	2.0	0
96	Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group. Clinical and Experimental Medicine, 2023, 23, 4199-4217.	3.6	0
97	Treatment Algorithm of Essential Thrombocythemia. , 2023, , 523-538.		0
98	Diagnosis and Management of Prefibrotic Primary Myelofibrosis (Pre-PMF). , 2023, , 549-557.		0
99	Impact of non�driver gene mutations on thrombo�haemorrhagic events in <scp>ET</scp> patients. British Journal of Haematology, 0, , .	2.5	0
100	Molecular diagnostic criteria of myeloproliferative neoplasms. Expert Review of Molecular Diagnostics, 2023, 23, 1077-1090.	3.1	0
101	Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience. Annals of Hematology, 0, , .	1.8	1
102	One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer Journal, 2024, 14, .	6.2	3
103	One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer Journal, 2024, 14, .	6.2	3
104	Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2024, 99, 697-718.	4.1	1
105	Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome. Frontiers in Oncology, 0, 14, .	2.8	0
106	A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery. Cureus, 2024, , .	0.5	0